Hims & Hers is a brave bet on solving the disruptor’s dilemma
Plan to make longevity affordable means muscling in on territory occupied by drugs giants and pharmacies
Related reading
Hims shares shoot up after weight-loss drug deal with Novo Nordisk
US telehealth group and Danish drugmaker have been in dispute over copycat medicines
Novo Nordisk hits out at rival Hims & Hers over cheaper weight-loss pill
US telehealth group will sell product for $49 a month, a third that of its Danish competitor
Novo Nordisk ends Hims & Hers tie-up over copycat Wegovy drugs
Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments
Hims & Hers abandons copycat weight-loss drug in face of FDA probe
Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy
The risky bet by AI start-ups
Broader, integrated software platforms for business will win out against those selling specific services
Healthcare companies set for deals spree as drug patents expire
A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump’s policies